Skip to main content

Advertisement

SpringerLink
Log in

HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis

  • Original Paper
  • Published:
Immunogenetics Aims and scope Submit manuscript

Abstract

Available data have led to a controversy on the relationship between human leukocyte antigen (HLA) and cutaneous malignant melanoma susceptibility or prognosis. Moreover, the influence of HLA-C on melanoma has not yet been well established. Therefore, the aim of the current study was to analyze the possible influence of the HLA system on melanoma susceptibility and prognosis in the Spanish population. For this purpose, HLA-A and HLA-B serotyping and HLA-C, HLA-DRB1, and HLA-DQB1 genotyping by polymerase chain reactions using sequence-specific oligonucleotide (PCR-SSO) and sequence-specific primer (PCR-SSP) were performed in 174 melanoma patients and 227 ethnically matched controls. The number of controls was increased up to 356 for HLA-C typing. Patients were stratified according to the histological subtypes of melanoma, sentinel lymph node status, tumor thickness, and ulceration of primary lesion. No HLA-A, HLA-B, HLA-DRB1, or HLA-DQB1 relationship with melanoma was observed for susceptibility or disease prognosis. However, the analysis of HLA-C locus showed that individuals homozygous for HLA-CLys80 were significantly more frequent within the patient than the control group. Remarkably, individuals homozygous for group 2 HLA-C alleles (HLA-CLys80) seem to be associated with metastatic progression of melanoma. In contrast, we found a negative association between group 1 HLA-C alleles (HLA-CAsn80) and disease susceptibility or metastasis development. In conclusion, although an association with HLA-A, HLA-B, HLA-DRB1, or HLA-DQB1 was not demonstrated, the study of the HLA-C locus revealed that the analysis of the dimorphism at position 80 in the α1 helix may help to evaluate the risk and prognosis of melanoma in our population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J Immunol 160:5239–5245

    PubMed  CAS  Google Scholar 

  • Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Feming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  • Barger BO, Acton RT, Soong SJ, Roseman J, Balch C (1982) Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 42:4276–4279

    PubMed  CAS  Google Scholar 

  • Bateman AC, Turner SJ, Theaker JM, Howell WM (1998) HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 52:67–73

    PubMed  CAS  Google Scholar 

  • Benlalam H, Labarrière N, Linard B, Derre L, Diez E, Pandolfino MC, Bonneville M, Jotereau F (2001) Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotheraphy. Eur J Immunol 31:2007–2015

    Article  PubMed  CAS  Google Scholar 

  • Boon T, Gajewski FT, Coulie PG (1995) From defined human tumor antigens to effective immunization. Immunol Today 16:334–336

    Article  PubMed  CAS  Google Scholar 

  • Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expresion in human tumor tissues. Cancer Immunol Immunother 52:1–9

    PubMed  CAS  Google Scholar 

  • Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Shuartz P, Glass A, Hildesheim A (2005) Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201:1069–1075

    Article  PubMed  CAS  Google Scholar 

  • Colonna M, Borsellingo G, Falco M, Ferrara GB, Strominger JL (1993) HLA-C is the inhibitory ligand that determined dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 90:12000–12004

    Article  PubMed  CAS  Google Scholar 

  • Fan QR, Long EO, Wiley DC (2001) Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1–HLA-Cw4 complex. Nat Immunol 2:452–460

    PubMed  CAS  Google Scholar 

  • Ghiorzo P, Bianchi Scar GB (2003) Genetics of melanoma susceptibility. Forum 13:114–126

    PubMed  Google Scholar 

  • Herman J, Van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG (1996) A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43:377–383

    Article  PubMed  CAS  Google Scholar 

  • Hiby SE, Walker JJ, O’Shaughnessy KM, Redman CWG, Carrington M, Trowsdale J, Moffett A (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 200:957–965

    Article  PubMed  CAS  Google Scholar 

  • Huard B, Karlsson L (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 30:1665–1675

    Article  PubMed  CAS  Google Scholar 

  • Igarashi T, Wynberg J, Srinivasan R, Becknell B, Phillip McCoy J Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170–177

    Article  PubMed  CAS  Google Scholar 

  • Jovic V, Konjevic G, Radulovic S, Jelic S, Spuzic I (2001) Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87:324–329

    PubMed  CAS  Google Scholar 

  • Kageshita T, Naruse T, Hirai S, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H, Ono T (1996) HLA class I antigens in Japanese patients with melanoma. J Immunother Emphasis Tumor Immunol 19:428–432

    PubMed  CAS  Google Scholar 

  • Kageshita T, Naruse T, Hirai S, Ono T, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H (1997) Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens 49:466–470

    PubMed  CAS  Google Scholar 

  • Kawasaki ES (1990) Sample preparation from blood, cells, and other fluids. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds) PCR protocols: a guide methods and application. Academic, New York

    Google Scholar 

  • Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Chen J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O’Brien SJ, Rosenberg WM, Thomas DL, Carrington M (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872–874

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A (2001) In vitro anti-tumor activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer 85:741–746

    Article  PubMed  CAS  Google Scholar 

  • Lanier LL (1997) Natural killer cells: from no receptors to too many. Immunity 6:371–378

    Article  PubMed  CAS  Google Scholar 

  • Lee JE, Reveille JD, Ross MI, Platsoucas CD (1994) HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 59:510–513

    Article  PubMed  CAS  Google Scholar 

  • Lee PP, Yee C, Savage PA, Fong L, Brokstedt D, Weber J, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677–685

    Article  PubMed  CAS  Google Scholar 

  • Lombardi ML, Mercuro O, Pirozzi G, Ionna F, Lombarda V, Mozzillo N, Manzo C (1998) Molecular analysis of HLA-DRB1 and DQB1 polymorphism in Italian melanoma patients. J Immunother 21:435–439

    Article  PubMed  CAS  Google Scholar 

  • Lulli P, Grammatico P, Brioli G, Catricala C, Morellini M, Roccella M, Mariani B, Pennesi G, Roccella F, Cappellacci S, Trabace S (1998) HLA-DR and -DQ alleles in Italian patients with melanoma. Tissue Antigens 51:276–280

    PubMed  CAS  Google Scholar 

  • Luongo V, Pirozzi G, Caraco C, Errico S, de Angelis F, Celentano E, Paino F, Chiofalo MG, Luongo M, Mozzillo N, Lombardi ML (2004) HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 64:84–87

    Article  PubMed  CAS  Google Scholar 

  • Mandelboim O, Reyburn HT, Valés-Gómez M, Pazmany L, Colonna M, Borsellino G, Strominger JL (1996) Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 184:913–922

    Article  PubMed  CAS  Google Scholar 

  • Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818–2822

    PubMed  CAS  Google Scholar 

  • Mueller-Eckhardt G, Schendel DJ, Hundeiker M, Riedel T, O’Neill GJ, Riethmuller G, Mueller-Echardt C (1984) Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int J Cancer 34:751–755

    Article  PubMed  CAS  Google Scholar 

  • Muto M, Ohmura A, Nakano J, Yamazaki N, Yamamoto A, Ishihara K, Sasazuki T, Asagami C (1996) HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 47:447–449

    PubMed  CAS  Google Scholar 

  • Nagore E, Planelles MD, Ledesma E, Millan JM, Insa A, Oliver V, Guillen C, Fortea JM (2002) Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma. Acta Derm Venereol 82:90–93

    Article  PubMed  CAS  Google Scholar 

  • Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54:172–178

    Article  PubMed  CAS  Google Scholar 

  • Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M (2004) Heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173:4273–4276

    PubMed  CAS  Google Scholar 

  • Nikitina-Zake L, Rajalingham R, Rumba I, Sanjeevi CB (2004) Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls. Ann N Y Acad Sci 1037:161–169

    Article  PubMed  CAS  Google Scholar 

  • Parham P (2004) NK cells lose their inhibition. Science 305:786–787

    Article  PubMed  CAS  Google Scholar 

  • Rajagopalan S, Long EO (2005) Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 201:1025–1029

    Article  PubMed  CAS  Google Scholar 

  • RA, Rodriguez JM, Moya MR, Galindo PJ, Canteras M, Álvarez MR, Parrilla P (2004) Frequency of HLA-C alleles in differentiated thyroid carcinoma in south-eastern Spain. Cancer 100:264–269

    Article  PubMed  CAS  Google Scholar 

  • Rees RC, Mian S (1999) Selective MHC expression in tumours modulates adaptive and innate antitumor responses. Cancer Immunol Immunother 48:374–381

    Article  PubMed  CAS  Google Scholar 

  • Rovini D, Sacchini V, Codazzi V, Vaglini M, Illeni MT (1984) HLA antigens in malignant melanoma patients. A second study. Tumori 70:29–33

    PubMed  CAS  Google Scholar 

  • Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P (2001) A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57:103–109

    Article  PubMed  CAS  Google Scholar 

  • Svejgaard A, Ryder LP (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43:18–27

    Article  PubMed  CAS  Google Scholar 

  • Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN (1995) Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772–779

    PubMed  CAS  Google Scholar 

  • Terasaki PI, McClelland JD, Park MS, McCurdy B (1974). Microdoplet assay of human serum cytotoxins. In: Ray JG, Hare DB, Pederson PD, Kayhoe DE (eds) Manual of tissue typing techniques. Department of Health, Education and Welfare Publications, Washington, DC

    Google Scholar 

  • Timonen T, Helander TS (1997) Natural killer cell–target cell interactions. Curr Opin Cell Biol 9:667–673

    Article  PubMed  CAS  Google Scholar 

  • Valés-Gómez M, Reyburn HT, Erskine RA, Strominger J (1998) Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A 95:14326–14331

    Article  PubMed  Google Scholar 

  • Vitale M, Sivori S, Pende D, Moretta L, Moretta A (1995) Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill normal allogeneic target cells. Proc Natl Acad Sci U S A 92:3536–3540

    Article  PubMed  CAS  Google Scholar 

  • Vivier E, Anfossi N (2004) Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev 4:190–198

    Article  CAS  Google Scholar 

  • Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T (1994) Two tyrosinase nonapeptides recognized HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759–764

    Article  PubMed  CAS  Google Scholar 

  • Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastastic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168–16173

    Article  PubMed  CAS  Google Scholar 

  • Zennadi R, Abdel-Wahab Z, Seigler HF, Darrow TL (2001) Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol 210:96–105

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank J.M. Alemany, M.J. Sanchis, M. Lopez, and M.C. Garcia Calatayud for their excellent technical assistance. This work was financially supported by the Seneca projects PI-400811/FS/01 and AR 1-02632/FS/02, by the Fondo de Investigacion Sanitaria (FIS) Program of Redes Tematicas de Investigacion, project G0/3104, and by Caja Murcia Foundation. J.A. Campillo is a postdoctoral researcher supported by the Spanish Health Ministry FIS (CM0300073).

Author information

Authors and Affiliations

  1. Immunology Service, Virgen de la Arrixaca University Hospital, Ctra. Madrid-Cartagena, 30120, El Palmar, Murcia, Spain

    José A. Campillo, Manuel Muro, Rosa Moya-Quiles, Luis A. Marín, Olga Montes-Ares, Natalia Guerra, Ana M. García-Alonso & M. Rocío Álvarez-López

  2. Dermatology Department, Virgen de la Arrixaca University Hospital, Murcia, Spain

    Jorge A. Martínez-Escribano, Paloma Sánchez-Pedreño & José F. Frías

  3. Department of Biochemistry and Molecular Biology, School of Medicine, University of Murcia, Murcia, Spain

    José A. Lozano

Authors
  1. José A. Campillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge A. Martínez-Escribano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Muro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosa Moya-Quiles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luis A. Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olga Montes-Ares
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Natalia Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paloma Sánchez-Pedreño
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. José F. Frías
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. José A. Lozano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ana M. García-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Rocío Álvarez-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Rocío Álvarez-López.

Additional information

The contributions by José A. Campillo and Jorge A. Martínez-Escribano are equal, and the order of authorship is arbitrary

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campillo, J.A., Martínez-Escribano, J.A., Muro, M. et al. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. Immunogenetics 57, 926–933 (2006). https://doi.org/10.1007/s00251-005-0065-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00251-005-0065-2

Keywords

Search

Navigation